Haruropi tape (ropinirole transdermal) / Hisamitsu, Kyowa Kirin - LARVOL DELTA

Update on Treatments for Parkinson's Disease Motor Fluctuations - An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review. (PubMed, Mov Disord) - "There are several treatment options that can improve motor fluctuations in PD. These recommendations will assist physicians and patients in determining which intervention to use."

Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

Switching from oral ropinirole to ropinirole transdermal patch in patients with Parkinson's Disease: an observational study. (PubMed, Neurol Neurochir Pol) - No abstract available

Journal • Observational data • CNS Disorders • Movement Disorders • Parkinson's Disease

Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson's disease - network meta-analysis. (PubMed, NPJ Parkinsons Dis) - "According to the surface under the cumulative ranking curve (SUCRA) in the NMA, ropinirole transdermal patch (SUCRA, 0.861) ranked the highest in efficacy, followed by pramipexole (0.762), ropinirole extended release (ER) (0.750), and safinamide (0.691). Each anti-PD drug had different SUCRA ranking profiles for the safety outcomes. These findings suggest that ropinirole, pramipexole, and safinamide are well-balanced anti-PD drugs that satisfy both efficacy and tolerability outcomes."

Journal • Retrospective data • CNS Disorders • Hypotension • Movement Disorders • Parkinson's Disease • ADORA2A

Efficacy and Safety of Non-Ergot Dopamine-receptor Agonists as an Adjunct to Levodopa in Advanced Parkinson's Disease: A Network Meta-Analysis. (PubMed, Eur J Neurol) - "This network meta-analysis suggests six commonly used NEDAs are effective as an adjunct to levodopa in advanced PD. In comprehensive consideration of better symptomatic management, ropinirole PR may be a better choice than other NEDAs in advanced PD. Six NEDAs showed different profiles of AEs."

Journal • Retrospective data • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

Comparison of efficacy and safety of adjunct treatments to levodopa in patients with Parkinson’s disease and wearing-off: A network meta-analysis of randomized, double-blind trials (MDS Congress 2022) - "Twelve drugs available in Japan for PD patients with wearing-off (pramipexole IR/ER, ropinirole IR/ER/transdermal patch, rotigotine transdermal patch, entacapone, opicapone, istradefylline, selegiline, rasagiline, and safinamide) were included in the study...For Off-time, 11 out of 12 active drugs were superior to placebo, and SUCRA was greater for ropinirole transdermal patch (86.1%), pramipexole IR (76.2%), ropinirole ER (75.0%), and safinamide (69.1%)... We found balanced efficacy and tolerability in dopamine agonists and safinamide. Further studies will be needed since the number of head to head trials was limited."

Retrospective data • CNS Disorders • Parkinson's Disease

Release of Ropinirole in Acrylate Transdermal Patches: Mutual Interactions Between Formulation Variables. (PubMed, AAPS PharmSciTech) - "The aim of this study is to evaluate the cooperative interactions between formulation variables of ropinirole transdermal patches and characterize the effects of drug loading and crystallinity, degree of ionization and drug-polymer solubilization, functionalization of acrylate polymeric basis, and the addition of permeation enhancers over the release profiles. The vinyl acetate comonomer reduces the drug release rate most effectively in formulations with low drug loads. The acrylic polymers without vinylacetate achieved the highest drug solubilization and thus the highest degree of release, providing a release of approximately 15% of the drug load."

Journal

Long-term study of ropinirole patch in Parkinson's disease patients with/without basal l-dopa. (PubMed, Parkinsonism Relat Disord) - "Once-daily application of ropinirole patch showed long-term efficacy and safety (52 weeks) for Parkinson's disease. Switching from other dopamine agonists to ropinirole patch was effective and safe. The plasma ropinirole concentration was at steady state throughout the study period and showed a dose-proportional increase."

Clinical • Journal • CNS Disorders • Dermatology • Movement Disorders • Parkinson's Disease

Kyowa Kirin to launch Haruropi tape for Parkinson’s disease in Japan (Kyowa Hakko Kirin Pharma Press Release) - “Kyowa Kirin Co., Ltd...announced that HARUROPI® TAPE will be launched in Japan on December 17th, 2019…Under the terms of the agreement signed with Hisamitsu Pharmaceutical in February 2019, Kyowa Kirin is responsible for commercializing HARUROPI® TAPE in Japan.”

Launch Japan

Kyowa Kirin announces approval of new transdermal patch Haruropi tape (HP-3000) for Parkinson's disease in Japan (Kyowa Hakko Kirin Pharma Press Release) - "Kyowa Kirin Co., Ltd....today announced that Hisamitsu Pharmaceutical Co., Inc....has received an approval for manufacturing and marketing HARUROPI® TAPE for the treatment of Parkinson's disease from Japan's Ministry of Health, Labour and Welfare (MHLW)."

Japanese regulatory

Hisamitsu Pharmaceutical and Kyowa Hakko Kirin sign commercialization agreement for HP-3000, a potential new transdermal patch for Parkinson's disease in Japan (Kyowa Hakko Kirin Pharma Press Release) - "Hisamitsu Pharmaceutical...announced that they have entered an agreement granting Kyowa Hakko Kirin exclusive rights to commercialize HP-3000...Hisamitsu Pharmaceutical submitted a new drug application for the product in September 2018 and the product is expected to be approved by February, 2020."

Japanese regulatory • Licensing / partnership